Zhou Gehong, Hu Yingshun, Wang Sumin
Department of Stomatology, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China.
Cranio. 2024 Oct 29:1-10. doi: 10.1080/08869634.2024.2419845.
We reviewed the efficacy of dextrose prolotherapy versus placebo and other active interventions, like autologous blood injection (ABI) and botulinum toxin (BTX), in improving the outcomes of temporomandibular joint (TMJ) hypermobility.
We searched PubMed, the Cochrane CENTRAL library, Embase, Scopus, and Web of Science databases to identify randomized controlled trials (RCTs) . Maximal mouth opening (MMO), pain, and frequency of dislocations were analyzed.
Eight RCTs were included. In comparison with placebo, dextrose prolotherapy was associated with significantly reduced pain and MMO. Comparison of dextrose with ABI revealed no significant difference in MMO. Qualitative analysis showed no significant difference in outcomes in patients who received dextrose prolotherapy and BTX.
Low-quality evidence suggests that dextrose prolotherapy may reduce MMO and improve pain scores compared to placebo in patients with TMJ hypermobility. Low-quality evidence also suggests that there may be minimal difference in outcomes between dextrose vs ABI and BTX.
我们回顾了葡萄糖注射疗法与安慰剂以及其他积极干预措施（如自体血注射（ABI）和肉毒杆菌毒素（BTX））相比，在改善颞下颌关节（TMJ）活动度过高方面的疗效。
我们检索了PubMed、Cochrane中央图书馆、Embase、Scopus和科学网数据库，以识别随机对照试验（RCT）。分析了最大开口度（MMO）、疼痛和脱位频率。
纳入了八项随机对照试验。与安慰剂相比，葡萄糖注射疗法与疼痛和最大开口度显著降低相关。葡萄糖与自体血注射在最大开口度方面无显著差异。定性分析表明，接受葡萄糖注射疗法和肉毒杆菌毒素治疗的患者在疗效上无显著差异。
低质量证据表明，与安慰剂相比，葡萄糖注射疗法可能会降低TMJ活动度过高患者的最大开口度并改善疼痛评分。低质量证据还表明，葡萄糖与自体血注射以及肉毒杆菌毒素在疗效上可能差异极小。
